NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics said Tuesday that it has raised $5.4 million in a Series A financing from Morningside Ventures.

The company plans to use the funding to develop diagnostic tests based on its RNAscope technology.

The RNAscope is a multiplex fluorescent and chromogenic in situ hybridization platform used to detect and quantify RNA biomarkers. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.